Sarcoidosis

American Family Physician

Volumn 70, Issue 2, 2004, Pages 312-322

  Wu, Jennifer J ^a,b   Schiff, Karin Rashcovsky ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC AGENT; DOXYCYCLINE; FLUTICASONE PROPIONATE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; MINOCYCLINE; PENTOXIFYLLINE; PREDNISONE; SALCATONIN; STEROID; THALIDOMIDE; VITAMIN D;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REDUCTION; GRANULOMATOSIS; HEART TRANSPLANTATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; IRIDOCYCLITIS; LUNG TRANSPLANTATION; OSTEOPOROSIS; PATHOGENESIS; PROGNOSIS; RADIODIAGNOSIS; REVIEW; SARCOIDOSIS; DIFFERENTIAL DIAGNOSIS; PATHOPHYSIOLOGY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PROGNOSIS; SARCOIDOSIS; SARCOIDOSIS, PULMONARY;

EID: 3843127597     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
2. Costabel U. Sarcoidosis: clinical update. Eur Respir J Suppl 2001;32:56s-68s.
3. Newman LS, Rose CS, Maier LA. Sarcoidosis [published correction in N Engl J Med 1997;337:139]. N Engl J Med 1997;336:1224-34.
4. Newman LS, Rose CS, Maier LA. Sarcoidosis [published correction in N Engl J Med 1997;337:139]. N Engl J Med 1997;336:1224-34.
5. Judson MA, Thompson BW, Rabin DL, Steimel J, Knattereud GL, Lackland DT, et al. The diagnostic pathway to sarcoidosis. Chest 2003;123:406-12.
6. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O; Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002;121:24-31.
7. Paramothayan NS, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2004;(1):CD001114.
8. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002;121:32-9.
9. Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997;61:382-5.
10. Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991;49:71-6.
11. Rizzato G, Riboldi A, Imbimbo B, Torresin A, Milani S. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. Respir Med 1997;91:449-60.
12. Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993;10:56-61.
13. Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994;236:285-90.
14. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995;8:682-8.
15. du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TA. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999;13:1345-50.
16. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vase Diffuse Lung Dis 2000;17:60-6.
17. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002;8:470-6.
18. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999;14:1117-22.
19. Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:87-92.
20. Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis 1991;8:35-41.
21. Kataria YP. Chlorambucil in sarcoidosis. Chest 1980; 78:36-43.
22. Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:185-90.
23. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999;160:192-7.
24. Hilton JM, Cooper DM, Henry RL. Hydroxychloroquine therapy of diffuse pulmonary sarcoidosis in two Australian male children. Respirology 1997;2:71-4.
25. Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med 1997;156:1371-6.
26. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999;159:508-11.
27. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997;155:1665-9.
28. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis [published correction in Sarcoidosis Vasc Diffuse Lung Dis 2001;18:310]. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4.
29. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis [published correction in Sarcoidosis Vasc Diffuse Lung Dis 2001;18:310]. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4.
30. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001;135:27-31.
31. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002;122:227-32.
32. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32(5 pt 2):866-9.
33. Baughman RP. Therapeutic options for sarcoidosis: new and old. Curr Opin Pulm Med 2002;8:464-9.
34. Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2004;(1):CD003536.
35. Nunley DR, Hattler B, Keenan RJ, lacono AT, Yousem S, Ohori NP, et al. Lung transplantation for end-stage pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:93-100.
36. Rothova A. Ocular involvement in sarcoidosis. Br J Ophathalmol 2000;84:110-6.
37. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999;106:111-8.
38. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001;137:69-73.
39. Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995;52:875-9.
40. Stern BJ, Schonfeld SA, Sewell C, Krumholz A, Scott P, Belendiuk G. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol 1992;49:1065-72.
41. Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 1996;10:495-510.
42. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-8.